Citadel Advisors LLC 13D and 13G filings for Enliven Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:24 pm Sale |
2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN |
Citadel Advisors LLC | 1,734,094 3.700% |
-660,354 (-27.58%) |
Filing |
| 2024-02-14 6:18 pm Purchase |
2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN |
Citadel Advisors LLC | 426,857 0.600% |
426,857 (New Position) |
Filing |
| 2024-02-14 4:58 pm Purchase |
2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN |
Citadel Advisors LLC | 2,394,448 5.800% |
95,692 (+4.16%) |
Filing |
| 2023-03-06 4:11 pm Purchase |
2023-02-23 | 13G | Enliven Therapeutics, Inc. ELVN |
Citadel Advisors LLC | 2,298,756 5.600% |
2,298,756 (New Position) |
Filing |